Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
women \>=18 years;
locally advanced or metastatic breast cancer;
HER-2 overexpression (FISH + or IHC 3+);
\>=1 measurable lesion;
up to one prior anthracycline-based chemotherapy regimen in a metastatic setting.
You may not be if
pre-existing neuropathy \>=grade 2;
known CNS metastases;
congestive heart failure, or myocardial infarction within the last 6 months;
previous malignancies in last 5 years, except for cured basal cell cancer of the skin, or cancer in situ of the cervix.
Clareo Health | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
